(ETTX) – Globe Newswire
-
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022
-
Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference
-
Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference
-
ENTASIS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of ETTX and Encourages Investors to Contact the Firm
-
Innoviva to Acquire Entasis Therapeutics
-
Innoviva to Acquire Entasis Therapeutics
-
Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference
-
Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference
-
Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business Update
-
Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business Update
-
Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference
-
Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference
-
Entasis Therapeutics Presents SUL-DUR Topline Data from Phase 3 ATTACK Trial at ECCMID 2022 Conference
-
Entasis Therapeutics Presents SUL-DUR Topline Data from Phase 3 ATTACK Trial at ECCMID 2022 Conference
-
Entasis Therapeutics Announces Year End 2021 Financial Results and Provides Business Update
-
Entasis Therapeutics Announces Year End 2021 Financial Results and Provides Business Update
-
Entasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc.
-
Entasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc.
-
Entasis Therapeutics to Participate in H.C. Wainwright BioConnect 2022
-
Entasis Therapeutics to Participate in H.C. Wainwright BioConnect 2022
-
Entasis Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update
-
Entasis Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update
-
Entasis Therapeutics to Report Third Quarter 2021 Results and Host Conference Call November 4, 2021
-
Entasis Therapeutics to Report Third Quarter 2021 Results and Host Conference Call November 4, 2021
-
Zai Lab and Entasis Therapeutics Announce Positive Topline Results for Sulbactam-Durlobactam (SUL-DUR) from Phase 3 ATTACK Trial
-
Zai Lab and Entasis Therapeutics Announce Positive Topline Results for Sulbactam-Durlobactam (SUL-DUR) from Phase 3 ATTACK Trial
-
Entasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trial
-
Entasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trial
-
Entasis Therapeutics to Participate in the Cantor Fitzgerald Virtual Global Healthcare Conference
-
Entasis Therapeutics to Participate in the Cantor Fitzgerald Virtual Global Healthcare Conference
-
Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature
-
Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature
-
Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
-
Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
-
Entasis Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
-
Entasis Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
-
Entasis Therapeutics to Host Expert Perspectives Webinar on Acinetobacter Infections
-
Entasis Therapeutics to Host Expert Perspectives Webinar on Acinetobacter Infections
-
Entasis Therapeutics to Report Second Quarter 2021 Results and Host Conference Call August 12, 2021
-
Entasis Therapeutics to Report Second Quarter 2021 Results and Host Conference Call August 12, 2021
-
Entasis Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
-
Entasis Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
-
Entasis Therapeutics and Zai Lab Complete Patient Enrollment in the ATTACK Phase 3 Registrational Clinical Trial of Sulbactam-Durlobactam
-
Entasis Therapeutics and Zai Lab Complete Patient Enrollment in the ATTACK Phase 3 Registrational Clinical Trial of Sulbactam-Durlobactam
-
Entasis Therapeutics Expands Executive Leadership Team with the Appointment of Anna Diaz Triola as Chief Commercial Officer
-
Entasis Therapeutics Expands Executive Leadership Team with the Appointment of Anna Diaz Triola as Chief Commercial Officer
-
Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens
-
Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens
-
Entasis Therapeutics Introduces First-in-Class Candidate, ETX0462, and Presents Data on SUL-DUR and ETX0282CPDP at World Microbe Forum
-
Entasis Therapeutics Introduces First-in-Class Candidate, ETX0462, and Presents Data on SUL-DUR and ETX0282CPDP at World Microbe Forum
Back to ETTX Stock Lookup
